Objective: To develop, calibrate, and evaluate the test-retest reliability of a new patient-reported outcome measure of headache pain relevant for individuals with traumatic brain injury (TBI).
Setting: Six TBI Model Systems rehabilitation centers in the United States.
Participants: Adults with medically confirmed documentation of TBI.
Design: Cross-sectional calibration field testing and test-retest reliability analyses.
Main Measures: Traumatic Brain Injury-Quality of Life Headache Pain item bank.
Results: Thirteen headache pain items were calibrated as a unidimensional measure using data from 590 participants. The new measure was reliable (α = .98; item-total correlation range: 0.71-0.91). Item parameter estimates were estimated using Samejima's Graded Response Model and a 10-item calibrated short form was created. Simulation testing confirmed that both the computer-adaptive test and the short-form administrations were equivalent to the full item bank. One- to-2-week test-retest reliability of the computer-adaptive test was high (Pearson r and intraclass correlation coefficients = 0.81). Approximately two-thirds of the sample reported at least 1 headache symptom.
Conclusion: The Traumatic Brain Injury-Quality of Life Headache Pain item bank and short form provide researchers and clinicians with reliable measures of the subjective experience of headache symptoms for individuals with a history of TBI.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/HTR.0000000000000532 | DOI Listing |
J Patient Exp
January 2025
Veterans Health Administration Headache Centers of Excellence, US Department of Veterans Affairs, Orange, CT, USA.
In 2018, the Veterans Health Administration (VHA) established the original 19 Headache Centers of Excellence (HCoE) program, and an evaluation center. This study utilized a Veteran engagement group method to elicit input from Veteran patients living with chronic headache on daily needs, social determinants of health, and preferences and suggestions for headache programs, services, and research priorities. Four engagement groups were conducted between July 13 and August 22 of 2022 with Veterans who experience headache and received care at a VHA HCoE.
View Article and Find Full Text PDFJ Ethnopharmacol
January 2025
Posgrado en Botánica, Colegio Postgraduados Campus Montecillo Km. 36.5 Carretera México-Texcoco C.P. Montecillo, 56264, Texcoco Estado de México, México. Electronic address:
Ethnopharmacological Relevance: Taxus globosa Schltdl. (Taxaceae) is commonly named "Tejo mexicano". It's a Mexican plant known in folk medicine as a remedy for pain such as stomachache and headache, arthritis, gout, and other inflammatory conditions.
View Article and Find Full Text PDFAm J Emerg Med
January 2025
Departments of Emergency Medicine (EM) and Community Health Sciences, University of Calgary, Canada.
Study Hypothesis: Use of opioids for treatment of headache in the emergency department (ED) is associated with an increased 1-year risk of opioid-related adverse events.
Objective: To assess the safety and efficacy of opioid prescribing for ED patients with headache.
Methods: We performed a multicenter observational cohort study using linked administrative data.
Curr Pain Headache Rep
January 2025
Universidad de Alcalá, School of Medicine and Health Sciences, Department of Surgery, Medical and Social Sciences, Area of Human Anatomy and Embryology, Universidad de Alcalá, University Campus - C/ 19 Av de Madrid Km 33 600, 28871, Alcalá de Henares, Madrid, Spain.
Purpose Of Review: Low back pain (LBP) is considered an important issue of public health, with annual prevalence estimations almost achieving 60% of the worldwide population. Available treatments have a limited impact on this condition, although they allow to alleviate pain and recover the patient's quality of life. This review aims to go deeper on the understanding of this condition, providing an updated, brief, and concise whole picture of this common musculoskeletal problem.
View Article and Find Full Text PDFJ Neurol
January 2025
Clinical and Molecular Epidemiology, IRCCS San Raffaele Roma, Rome, Italy.
Objectives: To determine whether extending anti-CGRP mAb treatment beyond 3 years influences migraine course, we analyzed migraine frequency during the first month of treatment discontinuation following three 12-month treatment cycles (Ts).
Methods: This multicenter, prospective, real-world study enrolled 212 patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM) who completed three consecutive Ts of subcutaneous anti-CGRP mAbs. Discontinuation periods (D1, D2, D3) were defined as the first month after T1, T2, and T3, respectively.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!